WO1999044622A1 - Inorganic nitrite and organic acid in combination as topical antiviral composition - Google Patents
Inorganic nitrite and organic acid in combination as topical antiviral composition Download PDFInfo
- Publication number
- WO1999044622A1 WO1999044622A1 PCT/GB1999/000605 GB9900605W WO9944622A1 WO 1999044622 A1 WO1999044622 A1 WO 1999044622A1 GB 9900605 W GB9900605 W GB 9900605W WO 9944622 A1 WO9944622 A1 WO 9944622A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutically acceptable
- concentration
- acid
- use according
- weight
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Definitions
- the present invention relates to a complex of nitrogen oxides, arising from the interaction of nitrite and acid as an 5 antiviral composition for the treatment of viral diseases of the skin by topical application thereto.
- nitrogen oxide include particular NO which is of the importance particularly if acidified.
- US-A-5648101 provides a vaso-active composition comprising NO adapted for delivery to a body site inter alia by means of a 5 cream or ointment.
- the NO is generated from an admixture of ferrous sulphate, an organic acid and an inorganic nitrite and caused to be reactive in the presence of moisture adjacent or at the site. Acidification is not discussed.
- Another object of the invention is to provide a system for treatment of viral skin diseases which is less susceptible to mutation of viral DNA.
- the pharmaceutically acceptable acidifying agent or the pharmaceutically acceptable donor of nitrogen oxides or a precursor therefor is disposed in a pharmaceutically acceptable carrier or diluent therefor.
- the first and second waxy components comprise a paraffin.
- the acidifying agent is preferably a reducing organic acid or salt such as ascorbic acid or ascorbyl palmitate.
- the source of nitrogen oxides may be an alkali metal nitrite such as sodium nitrite.
- a reducing acid or salt thereof results in a product at the environment of use which comprises a major amount of NO which has significant and therapeutic and immunological effects .
- the antigen processing cells of the skin were seen to lose dendricity and drop from the epidermis so there were significantly fewer in the treated skin. As these cells behave in this way when activated and functioning to process a newly recognized antigen, this would seem to offer further evidence for an immunopotentiating role for the nitrogen oxide complex. Ki-67 staining for dividing cells did not differ in control or active sites. This would suggest that in warts, for example, the action is not one of reducing cell proliferation. - 20 -
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020007009698A KR20010041527A (ko) | 1998-03-02 | 1999-03-01 | 국소적 항바이러스성 조성물로서 무기 아질산염 및유기산의 조성 |
EP99937878A EP1059928A1 (en) | 1998-03-02 | 1999-03-01 | Inorganic nitrite and organic acid in combination as topical antiviral composition |
HU0101374A HUP0101374A3 (en) | 1998-03-02 | 1999-03-01 | Inorganic nitrite and organic acid in combination as topical antiviral composition |
CA002322199A CA2322199A1 (en) | 1998-03-02 | 1999-03-01 | Inorganic nitrite and organic acid in combination as topical antiviral composition |
BR9908617-4A BR9908617A (pt) | 1998-03-02 | 1999-03-01 | Nitroto inorgânico e ácido orgânico em combinação como uma composição antiviral tópica. |
PL99342755A PL342755A1 (en) | 1998-03-02 | 1999-03-01 | Inorganic nitrite and organic acid containing compositions as alocally acting antiviral preparations |
JP2000534223A JP2002505295A (ja) | 1998-03-02 | 1999-03-01 | 局所抗ウイルス組成物として組み合わせた無機亜硝酸塩及び有機酸 |
MXPA00008583A MXPA00008583A (es) | 1998-03-02 | 1999-03-01 | Nitrito inorganico y acido organico en combinacion como una composicion antiviral topica. |
NZ506678A NZ506678A (en) | 1998-03-02 | 1999-03-01 | Inorganic nitrite and organic acid in combination as topical antiviral composition |
AU32617/99A AU758264B2 (en) | 1998-03-02 | 1999-03-01 | Inorganic nitrite and organic acid in combination as topical antiviral composition |
US09/330,654 US6709681B2 (en) | 1995-02-17 | 1999-06-11 | Acidified nitrite as an antimicrobial agent |
NO20004302A NO20004302L (no) | 1998-03-02 | 2000-08-29 | Kombinasjon av uorganisk nitritt og organisk syre som topisk antiviral sammensetning |
US10/701,295 US20040105898A1 (en) | 1994-02-21 | 2003-11-03 | Acidified nitrite as an antimicrobial agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9804469.6 | 1998-03-02 | ||
GBGB9804469.6A GB9804469D0 (en) | 1998-03-02 | 1998-03-02 | Antiviral composition |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1995/000338 Continuation-In-Part WO1995022335A1 (en) | 1994-02-21 | 1995-02-17 | Acidified nitrite as an antimicrobial agent |
US69693096A Continuation-In-Part | 1994-02-21 | 1996-08-21 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/330,654 Continuation-In-Part US6709681B2 (en) | 1994-02-21 | 1999-06-11 | Acidified nitrite as an antimicrobial agent |
US09/330,654 Continuation US6709681B2 (en) | 1994-02-21 | 1999-06-11 | Acidified nitrite as an antimicrobial agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999044622A1 true WO1999044622A1 (en) | 1999-09-10 |
Family
ID=10827886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1999/000605 WO1999044622A1 (en) | 1994-02-21 | 1999-03-01 | Inorganic nitrite and organic acid in combination as topical antiviral composition |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP1059928A1 (ko) |
JP (1) | JP2002505295A (ko) |
KR (1) | KR20010041527A (ko) |
CN (1) | CN1270725C (ko) |
AU (1) | AU758264B2 (ko) |
BR (1) | BR9908617A (ko) |
CA (1) | CA2322199A1 (ko) |
GB (1) | GB9804469D0 (ko) |
HU (1) | HUP0101374A3 (ko) |
MX (1) | MXPA00008583A (ko) |
NO (1) | NO20004302L (ko) |
NZ (1) | NZ506678A (ko) |
PL (1) | PL342755A1 (ko) |
WO (1) | WO1999044622A1 (ko) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002017881A2 (en) * | 2000-08-30 | 2002-03-07 | Queen Mary & Westfield College | Transdermal pharmaceutical delivery composition |
WO2003013489A1 (en) * | 2001-08-03 | 2003-02-20 | Aberdeen University | Treatment of nail infections with no |
US8557300B2 (en) | 2005-05-19 | 2013-10-15 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
WO2014031491A2 (en) * | 2012-08-23 | 2014-02-27 | Nioxx Llc | Extended production of nitric oxide from microencapsulated chemical reactants |
US8795649B2 (en) | 2007-02-28 | 2014-08-05 | Invasive Animals Ltd. | Nitrite salts as poisons in baits for omnivores |
US8927030B2 (en) | 2003-07-09 | 2015-01-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
US8932650B2 (en) * | 2011-01-11 | 2015-01-13 | Kantian Skincare LLC | Multifunctional topical formulation for the treatment of acne vulgaris and other skin conditions |
EP3158990A1 (en) | 2015-10-21 | 2017-04-26 | Glano Tech Ltd | Formulation for release of nitric oxide |
EP3166593A4 (en) * | 2014-07-11 | 2018-02-07 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US10716805B2 (en) | 2018-03-19 | 2020-07-21 | Glanotech Limited | Formulation for release of nitric oxide |
WO2020245574A1 (en) | 2019-06-04 | 2020-12-10 | Thirty Respiratory Limited | Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract |
WO2020245573A1 (en) | 2019-06-04 | 2020-12-10 | Thirty Holdings Limited | Methods and compositions for generating nitric oxide and uses thereof |
US11077194B2 (en) | 2012-03-14 | 2021-08-03 | Novan, Inc. | Nitric oxide releasing pharmaceutical compositions |
WO2021214440A1 (en) | 2020-04-23 | 2021-10-28 | Thirty Respiratory Limited | Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2 |
WO2021214439A1 (en) | 2020-04-23 | 2021-10-28 | Thirty Respiratory Limited | Methods and compositions for treating and combatting tuberculosis |
US11285098B2 (en) | 2013-02-28 | 2022-03-29 | Novan, Inc. | Topical compositions and methods of using the same |
US11285171B2 (en) | 2018-03-01 | 2022-03-29 | Novan, Inc. | Nitric oxide releasing suppositories and methods of use thereof |
US11813284B2 (en) | 2013-08-08 | 2023-11-14 | Novan, Inc. | Topical compositions and methods of using the same |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130330244A1 (en) * | 2011-12-05 | 2013-12-12 | Nioxx Llc | Compositions and methods for topical nitric oxide generation |
CN109437134A (zh) * | 2018-10-26 | 2019-03-08 | 中国核电工程有限公司 | 氮氧化物的制备方法及装置 |
CN116617254A (zh) * | 2022-09-26 | 2023-08-22 | 杭州泽德医药科技有限公司 | 含硼酸、亚硝酸盐的抗病原微生物组合物及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923899A (en) * | 1987-12-22 | 1990-05-08 | Cetylite Industries, Inc. | Sterilant composition |
WO1995022335A1 (en) * | 1994-02-21 | 1995-08-24 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
US5573786A (en) * | 1993-06-23 | 1996-11-12 | Solco Basel Ag | Preparation for skin and mucous membrane |
-
1998
- 1998-03-02 GB GBGB9804469.6A patent/GB9804469D0/en not_active Ceased
-
1999
- 1999-03-01 CN CNB998035866A patent/CN1270725C/zh not_active Expired - Fee Related
- 1999-03-01 HU HU0101374A patent/HUP0101374A3/hu unknown
- 1999-03-01 WO PCT/GB1999/000605 patent/WO1999044622A1/en not_active Application Discontinuation
- 1999-03-01 CA CA002322199A patent/CA2322199A1/en not_active Abandoned
- 1999-03-01 PL PL99342755A patent/PL342755A1/xx not_active Application Discontinuation
- 1999-03-01 BR BR9908617-4A patent/BR9908617A/pt not_active Application Discontinuation
- 1999-03-01 NZ NZ506678A patent/NZ506678A/xx unknown
- 1999-03-01 MX MXPA00008583A patent/MXPA00008583A/es not_active Application Discontinuation
- 1999-03-01 KR KR1020007009698A patent/KR20010041527A/ko not_active Application Discontinuation
- 1999-03-01 EP EP99937878A patent/EP1059928A1/en not_active Ceased
- 1999-03-01 JP JP2000534223A patent/JP2002505295A/ja not_active Withdrawn
- 1999-03-01 AU AU32617/99A patent/AU758264B2/en not_active Ceased
-
2000
- 2000-08-29 NO NO20004302A patent/NO20004302L/no not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4923899A (en) * | 1987-12-22 | 1990-05-08 | Cetylite Industries, Inc. | Sterilant composition |
US5573786A (en) * | 1993-06-23 | 1996-11-12 | Solco Basel Ag | Preparation for skin and mucous membrane |
WO1995022335A1 (en) * | 1994-02-21 | 1995-08-24 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
Non-Patent Citations (4)
Title |
---|
"Sodium Nitrite", MATERIAL SAFETY DATA SHEET, 12 August 1996 (1996-08-12), XP002111729, Retrieved from the Internet <URL:www.jtbaker.com/msds/s4466.htm> [retrieved on 19990803] * |
HEATON C. L.: "The revival of nitric acid for the treatment of anogenital warts", CLINICAL PHARMACOLOGY &THERAPEUTICS, vol. 54, no. 1, July 1993 (1993-07-01), pages 107 - 111, XP002111731 * |
WELLER R. ET AL: "A randomized trial of acidified nitrite cream in the treatment of tinea pedis", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, vol. 38, no. 4, April 1998 (1998-04-01), pages 559- - 563, XP002111730 * |
YOSHIDA Y ET AL: "Induction and promotion of forestomach tumors by sodium nitrite in combination with ascorbic acid or sodium ascorbate in rats with or without N-methyl-N'-nitro-N-nitrosoguanidine pre-treatment.", INTERNATIONAL JOURNAL OF CANCER, (1994 JAN 2) 56 (1) 124-8., XP002111728 * |
Cited By (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002017881A2 (en) * | 2000-08-30 | 2002-03-07 | Queen Mary & Westfield College | Transdermal pharmaceutical delivery composition |
US8128964B2 (en) | 2000-08-30 | 2012-03-06 | Queen Mary & Westfield College | Transdermal pharmaceutical delivery composition |
WO2002017881A3 (en) * | 2000-08-30 | 2003-04-17 | Queen Mary & Westfield College | Transdermal pharmaceutical delivery composition |
US8114442B2 (en) | 2000-08-30 | 2012-02-14 | Queen Mary & Westfield College | Transdermal pharmaceutical delivery compositions |
AU2002318001B2 (en) * | 2001-08-03 | 2007-02-15 | Aberdeen University | Treatment of nail infections with NO |
HRP20040059B1 (en) * | 2001-08-03 | 2008-05-31 | Aberdeen University | Treatment of nail infections with no |
WO2003013489A1 (en) * | 2001-08-03 | 2003-02-20 | Aberdeen University | Treatment of nail infections with no |
US9381381B2 (en) | 2001-08-03 | 2016-07-05 | Aberdeen University | Treatment of nail infections with no |
US9700578B2 (en) | 2003-07-09 | 2017-07-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
US8927030B2 (en) | 2003-07-09 | 2015-01-06 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
US9675637B2 (en) | 2003-07-09 | 2017-06-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Use of nitrite salts for the treatment of cardiovascular conditions |
US9387224B2 (en) | 2003-07-09 | 2016-07-12 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Treatment of specific cardiovascular conditions with nitrite |
US8557300B2 (en) | 2005-05-19 | 2013-10-15 | University Of Cincinnati | Methods for treating bacterial respiratory tract infections in an individual using acidified nitrite |
US9750242B2 (en) | 2007-02-28 | 2017-09-05 | Invasive Animals Ltd. | Nitrite salts as poisons in baits for omnivores |
US8795649B2 (en) | 2007-02-28 | 2014-08-05 | Invasive Animals Ltd. | Nitrite salts as poisons in baits for omnivores |
US8932650B2 (en) * | 2011-01-11 | 2015-01-13 | Kantian Skincare LLC | Multifunctional topical formulation for the treatment of acne vulgaris and other skin conditions |
US11077194B2 (en) | 2012-03-14 | 2021-08-03 | Novan, Inc. | Nitric oxide releasing pharmaceutical compositions |
WO2014031491A3 (en) * | 2012-08-23 | 2014-05-30 | Nioxx Llc | Production of nitric oxide from microencapsulated reactants |
US9445996B2 (en) | 2012-08-23 | 2016-09-20 | Nioxx Llc | Extended production of nitric oxide from a microencapsulated nitrite salt and an aqueous acidified gel |
WO2014031491A2 (en) * | 2012-08-23 | 2014-02-27 | Nioxx Llc | Extended production of nitric oxide from microencapsulated chemical reactants |
US11285098B2 (en) | 2013-02-28 | 2022-03-29 | Novan, Inc. | Topical compositions and methods of using the same |
US11813284B2 (en) | 2013-08-08 | 2023-11-14 | Novan, Inc. | Topical compositions and methods of using the same |
US10322081B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US10736839B2 (en) | 2014-07-11 | 2020-08-11 | Novan, Inc. | Topical antiviral compositions, delivery systems, and methods of using the same |
EP3698775A1 (en) * | 2014-07-11 | 2020-08-26 | Novan Inc. | Topical antiviral compositions and methods of using the same |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US11040006B2 (en) | 2014-07-11 | 2021-06-22 | Novan, Inc. | Topical antiviral compositions, delivery systems, and methods of using the same |
EP3166593A4 (en) * | 2014-07-11 | 2018-02-07 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US11723858B2 (en) | 2014-07-11 | 2023-08-15 | Novan, Inc. | Topical antiviral compositions, delivery systems, and methods of using the same |
EP3158990A1 (en) | 2015-10-21 | 2017-04-26 | Glano Tech Ltd | Formulation for release of nitric oxide |
US11285171B2 (en) | 2018-03-01 | 2022-03-29 | Novan, Inc. | Nitric oxide releasing suppositories and methods of use thereof |
US10716805B2 (en) | 2018-03-19 | 2020-07-21 | Glanotech Limited | Formulation for release of nitric oxide |
WO2020245574A1 (en) | 2019-06-04 | 2020-12-10 | Thirty Respiratory Limited | Methods and compositions for generating nitric oxide and uses thereof to deliver nitric oxide via the respiratory tract |
WO2020245573A1 (en) | 2019-06-04 | 2020-12-10 | Thirty Holdings Limited | Methods and compositions for generating nitric oxide and uses thereof |
WO2021214439A1 (en) | 2020-04-23 | 2021-10-28 | Thirty Respiratory Limited | Methods and compositions for treating and combatting tuberculosis |
WO2021214440A1 (en) | 2020-04-23 | 2021-10-28 | Thirty Respiratory Limited | Nitric oxide or nitric oxide releasing compositions for use in treating sars-cov and sars-cov-2 |
Also Published As
Publication number | Publication date |
---|---|
CA2322199A1 (en) | 1999-09-10 |
HUP0101374A3 (en) | 2003-07-28 |
KR20010041527A (ko) | 2001-05-25 |
JP2002505295A (ja) | 2002-02-19 |
NZ506678A (en) | 2003-04-29 |
NO20004302L (no) | 2000-10-30 |
MXPA00008583A (es) | 2003-07-14 |
PL342755A1 (en) | 2001-07-02 |
GB9804469D0 (en) | 1998-04-29 |
CN1291897A (zh) | 2001-04-18 |
AU3261799A (en) | 1999-09-20 |
BR9908617A (pt) | 2000-12-05 |
HUP0101374A2 (hu) | 2001-08-28 |
AU758264B2 (en) | 2003-03-20 |
CN1270725C (zh) | 2006-08-23 |
EP1059928A1 (en) | 2000-12-20 |
NO20004302D0 (no) | 2000-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU758264B2 (en) | Inorganic nitrite and organic acid in combination as topical antiviral composition | |
US6709681B2 (en) | Acidified nitrite as an antimicrobial agent | |
EP1064946B1 (en) | Topical zinc compositions | |
Ågren | Studies on zinc in wound healing | |
US4503037A (en) | Composition for the treatment of epithelial injuries and process for the preparation thereof | |
US7198806B2 (en) | Composition and method for treatment and prevention of pruritis | |
US20030147970A1 (en) | Ionic silver complex | |
JP4700808B2 (ja) | フルボ酸、および種々の状態の処置におけるその使用 | |
JP4987209B2 (ja) | 瘢痕形成作用を有する医薬品を製造するためのビグアニド誘導体の使用 | |
KR20070092095A (ko) | 소독용 조성물 및 이의 제조 및 이용 방법 | |
AU645359B2 (en) | Lithium treatment | |
RU2636530C2 (ru) | Фармацевтическая композиция для лечения ран и ожогов | |
JP2005501068A (ja) | 特に眼科分野における適用のための外傷および損傷の治癒および/または修復のための治療に適したアミノ酸組成物 | |
RU2481834C2 (ru) | Антимикробная композиция для лечения ран и ожогов | |
JP2024509309A (ja) | 三環式ヘテロアリール基を有する化合物の用途 | |
JPS6054932B2 (ja) | 治療組成物 | |
CZ289788B6 (cs) | Topický přípravek pro zavádění peptidických farmak do ľivých organismů | |
JP3827259B2 (ja) | 表皮角質化促進剤 | |
RU2717674C1 (ru) | Лекарственное средство, усиливающее оксигенацию тканей при диабетической стопе, и способ его применения | |
CZ20003204A3 (cs) | Farmaceutický prostředek | |
MXPA00005595A (en) | Topical zinc compositions and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 99803586.6 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2322199 Country of ref document: CA Ref document number: 2322199 Country of ref document: CA Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 506678 Country of ref document: NZ Ref document number: 32617/99 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2000/008583 Country of ref document: MX Ref document number: 1020007009698 Country of ref document: KR Ref document number: PV2000-3204 Country of ref document: CZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999937878 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1999937878 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2000-3204 Country of ref document: CZ |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007009698 Country of ref document: KR |
|
WWG | Wipo information: grant in national office |
Ref document number: 32617/99 Country of ref document: AU |
|
WWR | Wipo information: refused in national office |
Ref document number: 1020007009698 Country of ref document: KR |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: PV2000-3204 Country of ref document: CZ |
|
WWR | Wipo information: refused in national office |
Ref document number: 1999937878 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999937878 Country of ref document: EP |